港股異動丨君實生物(1877.HK)漲5.51%創逾一個月新高 PD-1收到FDA完整回覆函
格隆匯5月3日丨君實生物(1877.HK)漲5.51%,報59.4港元創逾一個月新高,總市值541億港元。君實生物昨日發佈公吿,PD-1抗體特瑞普利單抗的上市申請收到FDA的完整回覆函(CRL),要求進行一項質控流程變更。君實生物認為該變更較容易完整。君實生物計劃在2022年仲夏之前重新遞交上市申請。完整回覆函中還提到,現場核查因為新冠疫情受阻,具體核查時間另行通知。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.